Stockscreener 앱 받기
32.23
0.93%
0.2833
전일 마감가:
$31.95
열려 있는:
$32.37
하루 거래량:
161.09K
Relative Volume:
0.14
시가총액:
$3.06B
수익:
-
순이익/손실:
$-115.88M
주가수익비율:
-24.05
EPS:
-1.34
순현금흐름:
$-104.72M
1주 성능:
-1.89%
1개월 성능:
-7.47%
6개월 성능:
+80.26%
1년 성능:
+408.65%
1일 변동 폭
$31.71
$32.80
1주일 범위
$29.82
$33.21
52주 변동 폭
$5.93
$38.12
엣지와이즈 Stock (EWTX) Company Profile
명칭
Edgewise Therapeutics Inc
전화
720-262-7002
주소
1715 38TH ST, BOULDER
EWTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| EWTX | 32.23 | 3.06B | 0 | -115.88M | -104.72M | -1.34 |
| VRTX | 450.39 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.43 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.81 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.90 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
엣지와이즈 Stock (EWTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-05-01 | 개시 | Truist | Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-04-13 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-28 | 개시 | Goldman | Neutral |
엣지와이즈 주식(EWTX)의 최신 뉴스
FY2024 Earnings Estimate for EWTX Issued By Leerink Partnrs - Defense World
What is Leerink Partnrs' Forecast for EWTX FY2024 Earnings? - MarketBeat
Orbimed Advisors LLC Adjusts Stake in Edgewise Therapeutics Inc - GuruFocus.com
FMR LLC Reduces Stake in Edgewise Therapeutics Inc - GuruFocus.com
Learn to Evaluate (EWTX) using the Charts - Stock Traders Daily
Edgewise Therapeutics Reports Third Quarter Financial Results and Business Highlights - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Price Target Raised to $45.00 - MarketBeat
Edgewise Therapeutics Reports Q3 Progress in Muscle Disease Trials - TipRanks
Edgewise Therapeutics Inc. (EWTX) Quarterly 10-Q Report - Quartzy
Edgewise boosts R&D spending with drug trials underway - BizWest
Edgewise Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - BioSpace
Edgewise Therapeutics stock hits 52-week high at $36.71 - Investing.com
Edgewise Therapeutics stock hits 52-week high at $36.71 By Investing.com - Investing.com UK
Critical Analysis: Prestige Consumer Healthcare (NYSE:PBH) versus Edgewise Therapeutics (NASDAQ:EWTX) - Defense World
abrdn plc Purchases Shares of 256,645 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics shares maintain price target on positive data By Investing.com - Investing.com Australia
Novo Holdings A S Sells 794,530 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Moody Aldrich Partners LLC Makes New Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics stock hits 52-week high at $35.34 - Investing.com
Edgewise Therapeutics stock hits 52-week high at $35.34 By Investing.com - Investing.com Canada
Edgewise Therapeutics Inc (EWTX)’s Market Momentum: Closing Strong at 32.99, Up 3.68 - The Dwinnex
Top investors say Edgewise Therapeutics Inc (EWTX) ticks everything they need - SETE News
Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 52-Week HighShould You Buy? - MarketBeat
Is it possible to buy Edgewise Therapeutics Inc(EWTX) shares at a good price now? - US Post News
EWTX (Edgewise Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
SG Americas Securities LLC Sells 34,544 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Piper Sandler Increases Edgewise Therapeutics (NASDAQ:EWTX) Price Target to $51.00 - Defense World
Minimal stock impact anticipated for Edgewise Therapeutics stock even with potential CK miss - Investing.com Canada
Edgewise Therapeutics (NASDAQ:EWTX) Shares Up 4.5% Following Analyst Upgrade - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Price Target Raised to $51.00 at Piper Sandler - MarketBeat
(EWTX) Technical Pivots with Risk Controls - Stock Traders Daily
Edgewise Therapeutics Inc (EWTX) Stock: Navigating Drops and Gains - The InvestChronicle
Chief Scientific Officer Russell Alan J sold 75,000 shares of Edgewise Therapeutics Inc [EWTX] - Knox Daily
Edgewise Therapeutics (NASDAQ:EWTX) Hits New 12-Month HighTime to Buy? - MarketBeat
A look into Edgewise Therapeutics Inc (EWTX)’s deeper side - SETE News
Financial Analysis: Edgewise Therapeutics Inc (EWTX)’s Ratios Unveil Key Insights - The Dwinnex
Was there any good news for Edgewise Therapeutics Inc (EWTX) stock in the last session? - US Post News
Dimensional Fund Advisors LP Buys 168,219 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (EWTX): A Hot Stock to Buy Now - Yahoo Finance
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down – Here’s What Happened - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownHere's What Happened - MarketBeat
Edgewise Therapeutics Inc [EWTX] Insider Activity: An Update for Investors - Knox Daily
Squarepoint Ops LLC Purchases 27,687 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Millennium Management LLC Purchases 613,251 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Trading 5.2% HigherStill a Buy? - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Trading 5.2% Higher – Still a Buy? - Defense World
Hypertrophic Cardiomyopathy Market Expected to Experience - openPR
Hypertrophic Cardiomyopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing - Barchart
Edgewise Therapeutics Insiders Sold US$2.6m Of Shares Suggesting Hesitancy - Simply Wall St
Chief Scientific Officer Russell Alan J sale 75,000 shares of Edgewise Therapeutics Inc [EWTX] - Knox Daily
엣지와이즈 (EWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
엣지와이즈 주식 (EWTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
Sep 20 '24 |
Option Exercise |
0.18 |
75,000 |
13,500 |
87,719 |
| Russell Alan J | Chief Scientific Officer |
Sep 20 '24 |
Sale |
28.27 |
75,000 |
2,120,101 |
12,719 |
| MOORE JOHN R | General Counsel |
Sep 20 '24 |
Option Exercise |
0.71 |
50,000 |
35,500 |
53,252 |
| MOORE JOHN R | General Counsel |
Sep 23 '24 |
Option Exercise |
0.71 |
20,922 |
14,855 |
24,174 |
| MOORE JOHN R | General Counsel |
Sep 20 '24 |
Sale |
28.37 |
50,000 |
1,418,510 |
3,252 |
| MOORE JOHN R | General Counsel |
Sep 23 '24 |
Sale |
27.63 |
20,922 |
578,064 |
3,252 |
| Donovan Joanne M. | CMO |
Sep 20 '24 |
Sale |
28.29 |
7,162 |
202,603 |
14,538 |
| Derakhshan Behrad | Chief Business Officer |
Sep 20 '24 |
Option Exercise |
1.93 |
42,068 |
81,191 |
57,189 |
| Derakhshan Behrad | Chief Business Officer |
Sep 20 '24 |
Sale |
29.03 |
42,068 |
1,221,133 |
15,121 |
| Carruthers R Michael | Chief Financial Officer |
Sep 20 '24 |
Option Exercise |
1.93 |
96,068 |
185,411 |
81,996 |
1.80%
0.42%
자본화:
|
볼륨(24시간):